Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

Society For Translational Oncology

The Oncologist: Prognostic Significance of TOP2A Gene Dosage in HER2-Negative Breast Cancer

Access Activity

Overview / Abstract:

Learning objectives
1. Describe the prognostic role of TOP2A gene dosage determined by quantitative PCR in HER2-negative breast cancer.
2. Describe the relationship between HER2 status and TOP2A status in breast cancer tumors

Background. Previous studies showed the prognostic and predictive impact of human epidermal growth factor receptor 2 (HER-2) gene alterations analyzed separately and jointly with topoisomerase II α (TOP2A) gene alterations; however, the role of TOP2A gene abnormalities alone has not been thoroughly investigated. Additionally, TOP2A aberrations were typically studied in HER-2-positive (HER-2+) tumors because these genes are frequently coamplified. Therefore, the knowledge concerning the impact of TOP2A abnormalities in HER-2-negative (HER-2−) patients is scarce. This study aimed to investigate the clinical significance of TOP2A anomalies in breast cancer patients with HER-2− and HER-2+ tumors.

Materials and Methods. Snap-frozen tumor samples from 322 consecutive stage I–III breast cancer patients were analyzed for TOP2A gene dosage using quantitative real-time PCR (qPCR).

Results. A high TOP2A gene dosage was found in 94 tumors (29%)—32% and 27% of HER-2+ and HER-2− tumors, respectively. The mean TOP2A gene dosages in the HER-2+ and HER-2− groups were 1.49 ± 1.03 and 1.09 ± 0.35, respectively. High TOP2A gene dosage had an inverse prognostic impact in terms of shorter disease-free survival (DFS) and overall survival (OS) times in the entire group and in both the HER-2− and HER-2+ subgroups. The unfavorable prognostic impact of TOP2A gene dosage was maintained in the multivariate Cox regression analysis in the entire group and in HER-2− patients.

Conclusions. A high gene dosage of TOP2A determined using qPCR occurs frequently both in HER-2+ and HER-2− tumors and has a strong adverse prognostic impact.

Expiration

Nov 19, 2014

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Journal, Online

Credits / Hours

The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accreditation

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

Presenters / Authors / Faculty

Anna J. Żaczek, Aleksandra Markiewicz, Barbara Seroczyńska, Jarosław Skokowski, Janusz Jaśkiewicz, Tadeusz Pieńkowski, Wojciech P. Olszewski, Jolanta Szade, Piotr Rhone, Marzena Wełnicka-Jaśkiewicz, Jacek Jassem

Activity Specialities / Related Topics

Genetics, OB/GYN / Women's Health, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

STO is pleased to acknowledge the receipt of educational grants from Pfizer and Genentech in partial support of these activities.

Keywords / Search Terms

Society For Translational Oncology Society For Translational Oncology Society For Translational Oncology, Regional ultrasound, Breast cancer, Staging, Locally advanced, Free CE CME Free CE CME Free CE CME

Access Activity

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.